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Abstract Osteogenesis imperfecta or ‘‘brittle bone dis-
ease’’ is a congenital disorder of connective tissue causing
the bone to break easily. Around 85–90% of cases are due
to autosomal dominant mutations in the genes encoding
type I collagen, the major organic component of bone.
Genotype–phenotype correlations have shown that quanti-
tative defects of collagen type I lead to mild OI, whereas
structural defects show a wide clinical range from mild to
perinatal lethal. This may partially be explained by the type
of amino acid substitution and the relative location in the
domain structure. To fully understand the variability of the
clinical manifestation and the underlying pathomecha-
nisms, further investigations are required. Here we provide
the first biochemical characterization of a mutation at the
signal peptide cleavage site of COL1A1, a domain not yet
characterized. By steady-state analysis, we observed
reduced production of collagen type I. Furthermore, by
pulse-chase analysis we detected delayed secretion and
partial intracellular retention of collagen I. In the cellular
fraction, the electrophoretic migration was abnormal;
however, secreted type I collagen showed a normal
migration pattern. The intracellular retention of collagen I
was confirmed by immunofluorescent staining. Moreover,
transmission electron microscopy of cultured fibroblasts
revealed enlargement of ER cisternae. These results further
support the hypothesis that mechanisms interfering with
ER integrity play an important role in the pathology of
severe OI.
Keywords Osteogenesis imperfecta  Bone  Collagen 
COL1A1  Signal peptide mutation  Signal peptide
cleavage site
Introduction
Osteogenesis imperfecta (OI; MIM 166,200, 1,666,210,
259,420, and 166,220) is a heterogeneous heritable disor-
der of bone matrix formation and remodeling. The cardinal
manifestations are bone fragility and deformity due to
hypermineralization of the bone matrix resulting in stiffer
bone tissue which is more prone to fractures [1–3]. Based
on clinical and radiological findings, individuals with OI
are classified according to Sillence as mild type I, perinatal
lethal type II, severe type III, or moderately deforming type
IV [4]. Around 85–90% of cases with OI are caused by
mutations in the genes COL1A1 (MIM 120,150) or
COL1A2 (MIM 120,160), encoding type I collagen [5].
Procollagen peptide chains in the rough endoplasmic
reticulum (rER) undergo a series of modifications, such as
hydroxylation and glycosylation, and assemble into a triple
helix consisting of two a1(I) chains and one a2(I) chain,
respectively. Glycine is required at every third position in
the helical part since it is the only amino acid small enough
to face into the inner side of the triple helix [6, 7]. After
secretion into the extracellular space and removal of the N-
and C-propeptides, the so-formed insoluble mature colla-
gen I molecules can assemble into fibrillar structures.
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Genotype–phenotype correlations have shown that
COL1A1 mutations leading to quantitative alterations of
the transcript, in particular to haploinsufficiency, are
associated with mild OI type I, whereas mutations leading
to structural defects result in a wide clinical spectrum from
mild to lethal forms. Glycine substitutions in the triple
helical part account for the majority of these mutations and
are associated with overmodification of the triple helix due
to delayed folding. Starting from 2006, several non-colla-
gen genes causing OI have been identified and shown to be
involved in collagen I biosynthesis, bone mineralization,
and osteoblast development (reviewed in [8]). Unfortu-
nately, the pathophysiological understanding could not
keep pace with the expanding insight into the genetic
heterogeneity of OI. Therefore, it remains unclear whether
common pathological mechanisms exist and whether these
are mainly determined by collagen deficiency, cellular
malfunction, or structural defects in the extracellular
matrix.
Here we provide novel insight into the pathophysiology
of OI by investigating a rare disease causing variant
localized in the signal peptide of COL1A1 [9], a hitherto
functionally uncharacterized domain (Fig. 1a).
A heterozygous de novo p.Gly22Arg mutation at the
- 1 position of the signal peptide cleavage site was iden-
tified in a fetus with severe OI, aborted at the 22nd week of
pregnancy (patient ID: AN_000079 in the osteogenesis
imperfecta variant database https://oi.gene.le.ac.uk/). The
same mutation has been reported previously in a patient
with OI type II [10]. Recently the p.Gly22-Gln23del
mutation (deletion of the - 1 and ? 1 positions of the
signal peptide) has been identified in a patient with OI type
III [11]. However, both cases were identified by epidemi-
ological studies and thus no biochemical characterization
was performed. Signal peptides contain a hydrophobic
core, which allows the targeting of the protein to the ER
upon translation, and a cleavage site which is required to
release the protein from the membrane pore (translocon).
Efficient cleavage by the signal peptidase requires small
amino acids (Ala, Gly, Ser) at the - 1 position of the
cleavage site [12]. To gain insight into the pathomecha-
nism of this form of OI, we set out to analyze collagen
biosynthesis and secretion, as well as the cellular
ultrastructure.
Methods and Results
Genetic Analysis
All coding exons and flanking exon–intron junctions of
COL1A1 and COL1A2 were Sanger sequenced using Big-
Dye Terminator version 3.1 cycle sequencing kit and an
ABI Prism 3100 automated DNA sequencer (Applied
Biosystems, Foster City, CA).
Cleavage Site Prediction
In silico analysis of the signal sequence was done by
submitting the first 50 amino acids of the COL1A1
sequence to the SignalP 4.1 server at http://www.cbs.dtu.
dk/services/SignalP/ [13].
A strong reduction of the cleavage probability (from
0.956 to 0.319) for the p.Gly22Arg substitution was pre-
dicted (Fig. 1b).
Cell Culture and Collagen Analyses
Fibroblasts of the fetus were obtained from an umbilical
cord biopsy by explant culture. Patient and control
fibroblasts were grown under standard conditions using
DMEM medium supplemented with 10% fetal calf serum,
100 units/ml of penicillin, 100 lg/ml of streptomycin, and
0.25 lg/ml of amphotericin B (Gibco). Fibroblasts of an
unaffected individual in pediatric age were used as a
control.
To assess possible effects on collagen biosynthesis and
secretion, we performed collagen steady-state and pulse-
chase analyses in cultured fibroblast as described [14] with
minor changes: 4-h pulse labeling of collagen with (3H)-
proline and (3H)-glycine was followed by chase with
unlabeled amino acids for 5, 30 min, 2 and 24 h.
Steady-state analysis showed that the proportion of type
I to type III collagen was reduced in the medium of the OI
fibroblasts compared to the control (Fig. 2a).
Pulse-chase analysis showed that the secretion of the
a1(I) and the a2(I) chains from the cells into the medium
was slightly delayed in the OI fibroblasts (Fig. 2b). A small
amount of type I collagen was retained in the cells even
after 24 h (arrow, Fig. 2b). Furthermore, in the cell layer,
but not in the medium of the OI cells, the a1(I) and
a2(I) chains appeared as slightly broad and fuzzy bands,
suggesting the presence of both overmodified as well as
undermodified collagen chains in the 5-min, 30-min, and
2-h chases (Fig. 2b).
Immunofluorescent Staining
To further investigate the intracellular distribution of col-
lagen in the OI and control fibroblasts, co-immunofluo-
rescent staining for type I collagen (COLI; mouse anti-
collagen I Abcam ab6308; 1:100) and either the ER marker
protein disulfide isomerase (PDI; rabbit anti-PDI Santa
Cruz sc-20,132) or the Golgi marker GM130 (rabbit anti-
GM130 Abcam ab52649; 1:100) was performed as
described [14]. Secondary antibodies were goat anti-rabbit
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AF568 (ab175471) Abcam (1:500) and goat anti-mouse
AF488 (A11017) Molecular Probes (1:500). Nuclei were
stained with 40,6-diamidino-2-phenylindole (DAPI). Type I
collagen localized to the ER as well as to the Golgi in OI as
well as control fibroblasts. Additionally, in the OI fibrob-
lasts, a punctuate staining not overlapping with the ER or
Golgi markers was observed (Fig. 2c).
Fig. 1 a Domain structure of COL1A1 protein with p.Gly22Arg
substitution in the signal peptide highlighted in blue. b Prediction of
the cleavage site probability of the wt COL1A1 sequence and the
p.Gly22Arg substitution using the SignalP algorithm. The algorithm
predicts a strong reduction of the cleavage site probability (from
0.956 to 0.319) for the p.Gly22Arg substitution. The predicted
cleavage site for the Gly22Arg substitution with the highest
probability is at a different position (between Gly30 and Gln31). A
black arrow indicates the position of the wt signal peptide cleavage
site; n-region: N-terminal region; h-region: hydrophobic region;
c-region: cleavage region (Color figure online)
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Fig. 2 Collagen synthesis and
secretion in fibroblasts cultures
of the OI fetus (OI) and a
control (Ctr.); a steady-state
analysis showing decreased
levels of type I collagen
a1(I) and a2(I) relative to type
III collagen [a1(III)]3 in the
medium (M) of the OI
fibroblasts suggesting that less
collagen type I was produced
and secreted by these cells;
b pulse-chase analysis showing
a decreased amount of type I
collagen chains secreted from
the cell layer (C) into the
medium layer (M) in the OI
fibroblasts compared to the
control in the 5-min, 30-min,
and 2-h chases. Also, bands
with a broader migration pattern
are visible in the cell layer
(C) of the OI fibroblasts (white
asterisk) and a small amount of
collagen is still visible after
24-h chase in the cell layer of
the OI sample (white
arrowhead) but not the control;
c Co-immunofluorescent
staining of type I collagen (COL
I) together with ER (PDI) or
Golgi (GM130) markers. DAPI
was used to stain nuclei and an
overlay of COL I with either
PDI or GM130 is given showing
increased staining for type I
collagen in the OI cells and only
partial overlap with ER and
Golgi markers
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Transmission Electron Microscopy
To investigate whether the morphology of the ER was
altered due to the putative retention of misfolded collagen,
we performed transmission electron microscopy on cul-
tured fibroblasts as described [14].
The OI cells (Fig. 3a, b) presented with enlarged cis-
ternae of the rough endoplasmic reticulum (rER) which
were not seen in control fibroblasts (Fig. 3c, d).
Discussion
Here we provide the first biochemical characterization of a
mutation in the signal peptide of COL1A1 leading to a
severe form of OI and discuss possible underlying
pathomechanisms.
Unfortunately, the availability of a single affected sub-
ject and the inaccessibility of osteoblasts present a limita-
tion of our study. Despite this drawback, we show that it
offers the opportunity to draw general conclusions on the
pathomechanism involved in OI.
Firstly, we observed decreased collagen secretion, sim-
ilar to the findings in OI with haploinsufficiency of
COL1A1. However, haploinsufficiency is strongly associ-
ated with mild OI suggesting for additional pathological
mechanisms responsible for the severe phenotype.
Furthermore, secretion of collagen I by the fibroblasts of
the OI fetus was slightly delayed, but both collagen I
chains showed a normal migration pattern suggesting that
structural alteration of the ECM do not account for the
severe phenotype in the fetus. This is in line with the fact
that the mutation lies in a domain that is not part of the
collagen fibrils in the ECM and also not involved in triple
helical folding or processing. Unfortunately, bone tissue for
mass spectrometry analysis was not available to defini-
tively rule out the presence of aberrant collagen in the
extracellular matrix.
Although the secreted type I collagen showed a normal
migration pattern, a portion of collagen with aberrant
modification appeared to be retained within the cell. The
reduced secretion and aberrant modification of intracellu-
larly retained collagen, not overlapping with the ER-lu-
minal marker, suggest that the p.Gly22Arg mutation
impairs cleavage and thus the release of preprocollagen
a1(I) chains from the ER-entry sites (translocon). This is
also supported by the results obtained by the in silico
prediction of the cleavage efficiency. Impaired release of
preprocollagen chains from the translocon might have
pleiotropic effects, .e.g., leading to misfolding and ER
stress or exhibiting a dominant negative effect on the
COL1A1 chain encoded by the normal allele. Furthermore,
blocking the translocon might affect cellular functioning
since this pore is required for ER entry of other proteins of
Fig. 3 Transmission electron microscopy (TEM) analysis of cultured fibroblasts showing enlarged ER cisterns in the cells of the fetus (a,
b) compared to a control (c, d)
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the secretory pathway, as well as for the export of mis-
folded proteins for ERAD or lysosomal degradation.
Consistently, we detected dilated ER cisterns by electron
microscopy, suggesting that ER stress might be involved in
the pathology of OI as shown previously in a study ana-
lyzing a G610C mouse model of OI [15].
Pathological effects of signal peptide mutations have
been characterized already in other genes (diseases) such as
insulin (diabetes), COL10A1 (Schmid-type metaphyseal
chondrodysplasia, MCDS), and COL5A1 (classical Ehlers–
Danlos Syndrome, cEDS). These reports have shown that
overall, mutations of the hydrophobic region cause protein
deficiency as shown for COL5A1 in cEDS, whereas
mutations of the cleavage site are associated with ER stress
and dominant negative effects on the remaining wild-type
protein as demonstrated for COL10A1 in MCDS and
insulin in diabetes [16–18]. Thus, our findings are in line
with previous reports on pathological effects of cleavage
site mutations.
Taken together, our data support the hypothesis that
intracellular mechanisms such as accumulation of unfolded
proteins and ER stress can contribute to the pathophysiol-
ogy of the more severe forms of OI (Sillence class II to IV).
We suggest, therefore, that therapeutic approaches for OI
aiming to increase the clearance of misfolded proteins
should be taken seriously into consideration.
Acknowledgements We thank Angelika Schwarze for expert tech-
nical assistance with fibroblast cultures. The work has been supported
by the Swiss National Science Foundation (SNF-Grant
310030_138288) to CG and MR.
Author Contributions UL wrote the manuscript, and CG and MR
participated in drafting the manuscript. UL, CG, and MR contributed
to the conception and design of the study. MG, MFB, MM, and LS
contributed to the acquisition of biological materials and performed
genetic analyses. All authors participated in revising the manuscript
and approved the final version of the manuscript for submission.
Compliance with Ethical Standards
Conflict of interest U. Lindert, M. Gnoli, M. Maioli, MF. Bedeschi,
L. Sangiorgi, M. Rohrbach, and C. Giunta declare that they have no
conflicts of interest.
Human and Animal Rights and Informed Consent This study was
conducted according to the Declaration of Helsinki for Human Rights
of 1975, as revised in 2000, and approved by Swiss Ethics. For the
study informed parental consent, in accordance with requirements of
the Institutional Ethic Committee of the referring physician (MFB),
was obtained.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Marini JC (ed) (2004) Nelson textbook of pediatrics Saunders,
Philadelphia
2. Martin E, Shapiro JR (2007) Osteogenesis imperfecta:epidemi-
ology and pathophysiology. Curr Osteoporos Rep 5(3):91–97
3. Phillipi CA, Remmington T, Steiner RD (2008) Bisphosphonate
therapy for osteogenesis imperfecta. Cochrane Database Syst Rev
4(4):005088
4. Sillence DO, Senn A, Danks DM (1979) Genetic heterogeneity in
osteogenesis imperfecta. J Med Genet 16(2):101–116
5. Marini JC, Forlino A, Cabral WA, Barnes AM, San Antonio JD,
Milgrom S, Hyland JC, Korkko J, Prockop DJ, De Paepe A,
Coucke P, Symoens S, Glorieux FH, Roughley PJ, Lund AM,
Kuurila-Svahn K, Hartikka H, Cohn DH, Krakow D, Mottes M,
Schwarze U, Chen D, Yang K, Kuslich C, Troendle J, Dalgleish
R, Byers PH (2007) Consortium for osteogenesis imperfecta
mutations in the helical domain of type I collagen: regions rich in
lethal mutations align with collagen binding sites for integrins
and proteoglycans. Hum Mutat 28(3):209–221
6. Bateman JF, Boot-Handford RP, Lamande SR (2009) Genetic
diseases of connective tissues: cellular and extracellular effects of
ECM mutations. Nat Rev 10(3):173–183
7. Grant Kielty (2002) The Collagen family: structure, assembly,
and oragnisation in the extracellular matrix. Connective tissue
and its heritable disorders. CV Mosby, St. Louis, pp 159–221
8. Kang H, Aryal ACS, Marini JC (2017) Osteogenesis imperfecta:
new genes reveal novel mechanisms in bone dysplasia. Transl
Res 181:27–48. https://doi.org/10.1016/j.trsl.2016.11.005
9. Tromp G, Kuivaniemi H, Stacey A, Shikata H, Baldwin CT,
Jaenisch R, Prockop DJ (1988) Structure of a full-length cDNA
clone for the prepro alpha 1(I) chain of human type I procollagen.
Biochem J 253(3):919–922
10. Pollitt R, McMahon R, Nunn J, Bamford R, Afifi A, Bishop N,
Dalton A (2006) Mutation analysis of COL1A1 and COL1A2 in
patients diagnosed with osteogenesis imperfecta type I–IV. Hum
Mutat 27(7):716. https://doi.org/10.1002/humu.9430
11. Lindahl K, Astrom E, Rubin CJ, Grigelioniene G, Malmgren B,
Ljunggren O, Kindmark A (2015) Genetic epidemiology, preva-
lence, and genotype-phenotype correlations in the Swedish pop-
ulation with osteogenesis imperfecta. Eur J Hum Genet
23(8):1112. https://doi.org/10.1038/ejhg.2015.129
12. Choo KH, Ranganathan S (2008) Flanking signal and mature
peptide residues influence signal peptide cleavage. BMC Bioin-
form 9(Suppl 12):S15. https://doi.org/10.1186/1471-2105-9-S12-
S15
13. Petersen TN, Brunak S, von Heijne G, Nielsen H (2011) SignalP
4.0: discriminating signal peptides from transmembrane regions.
Nat Methods 8(10):785–786. https://doi.org/10.1038/nmeth.1701
14. Lindert U, Weis MA, Rai J, Seeliger F, Hausser I, Leeb T, Eyre
D, Rohrbach M, Giunta C (2015) Molecular consequences of the
SERPINH1/HSP47 mutation in the dachshund natural model of
osteogenesis imperfecta. J Biol Chem 290(29):17679–17689.
https://doi.org/10.1074/jbc.M115.661025
15. Mirigian LS, Makareeva E, Mertz EL, Omari S, Roberts-Pilgrim
AM, Oestreich AK, Phillips CL, Leikin S (2016) Osteoblast
malfunction caused by cell stress response to procollagen mis-
folding in alpha2(I)-G610C mouse model of osteogenesis
imperfecta. J Bone Miner Res 31(8):1608–1616. https://doi.org/
10.1002/jbmr.2824
16. Chan D, Ho MS, Cheah KS (2001) Aberrant signal peptide
cleavage of collagen X in Schmid metaphyseal chondrodysplasia.
Implications for the molecular basis of the disease. J Biol Chem
276(11):7992–7997. https://doi.org/10.1074/jbc.M003361200
U. Lindert et al.: Insight into the Pathology of a COL1A1 Signal Peptide…
123
17. Liu M, Lara-Lemus R, Shan SO, Wright J, Haataja L, Barbetti F,
Guo H, Larkin D, Arvan P (2012) Impaired cleavage of pre-
proinsulin signal peptide linked to autosomal-dominant diabetes.
Diabetes 61(4):828–837. https://doi.org/10.2337/db11-0878
18. Symoens S, Malfait F, Renard M, Andre J, Hausser I, Loeys B,
Coucke P, De Paepe A (2009) COL5A1 signal peptide mutations
interfere with protein secretion and cause classic Ehlers-Danlos
syndrome. Hum Mutat 30(2):E395–E403. https://doi.org/10.
1002/humu.20887
U. Lindert et al.: Insight into the Pathology of a COL1A1 Signal Peptide…
123
